Estimated Dose Exposure of the Neonate to Buprenorphine and Its Metabolite Norbuprenorphine via Breastmilk During Maternal Buprenorphine Substitution Treatment
Authors:
- 19 October 2011
- journal article
- research article
- Published by SAGE Publications in Breastfeeding Medicine
- Vol. 7 (4) , 269-274
Abstract
Objective: The aim of the present study was to estimate the dose of buprenorphine and its primary metabolite norbuprenorphine that a breastfed infant would receive during maternal maintenance treatment with buprenorphine. Study Design: Seven pregnant opioid-dependent women taking buprenorphine (median, 7 mg/day; range, 2.4–24 mg) and who intended to breastfeed were recruited. After lactation was established, several milk samples were collected from each subject over a 24-hour dose interval, and buprenorphine and norbuprenorphine concentrations were measured by liquid chromatography–tandem mass spectrometry. The average concentration ( C avg ) across the dose interval was estimated as for both buprenorphine and norbuprenorphine (as buprenorphine equivalents). Absolute infant dose (AID), defined as C avg ×daily milk intake, and relative infant dose (RID), defined as 100×AID/weight-adjusted maternal daily dose, via milk were calculated, assuming a milk intake of 0.15 L/kg/day. The infant's health and progress were assessed directly and by questionnaire on the study day. Results: Mean (95% confidence interval) norbuprenorphine concentration in milk and AID values (1.94 [0.79–3.08] μg/L and 0.29 [0.12–0.46] μg/kg/day, respectively) were approximately half those for buprenorphine (3.65[1.61–5.7] μg/L and 0.55 [0.24–0.85] μg/kg/day, respectively). Similarly, the mean RID values were 0.18% (0.11–0.25%) for norbuprenorphine and 0.38% (0.23–0.53%) for buprenorphine. The breastfed infants showed no adverse effects, were all in good health, and were progressing as expected. Conclusion: Thus the dose of buprenorphine and norbuprenorphine received via milk is unlikely to cause any acute adverse effects in the breastfed infant.Keywords
This publication has 19 references indexed in Scilit:
- Observational Study of Buprenorphine Treatment of Opioid-Dependent Pregnant Women in a Family Medicine Residency: Reports on Maternal and Infant OutcomesThe Journal of the American Board of Family Medicine, 2011
- Contribution of the Different UDP-Glucuronosyltransferase (UGT) Isoforms to Buprenorphine and Norbuprenorphine Metabolism and Relationship with the Main UGT Polymorphisms in a Bank of Human Liver MicrosomesDrug Metabolism and Disposition, 2010
- Maternal Response to Two Electric Breast PumpsBreastfeeding Medicine, 2009
- Transfer of Buprenorphine Into Breast Milk and Calculation of Infant Drug DoseJournal of Human Lactation, 2009
- Buprenorphine and Norbuprenorphine Concentrations in Human Breast Milk Samples Determined by Liquid Chromatography-Tandem Mass SpectrometryTherapeutic Drug Monitoring, 2005
- Use of buprenorphine in pregnancy: patient management and effects on the neonateDrug and Alcohol Dependence, 2003
- Inhibition and Active Sites of UDP-Glucuronosyltransferases 2B7 and 1A1.Drug Metabolism and Disposition, 2002
- Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomesLife Sciences, 1997
- The Glucuronidation of Exogenous and Endogenous Compounds by Stably Expressed Rat and Human UDP-Glucuronosyltransferase 1.1Archives of Biochemistry and Biophysics, 1996
- Creamatocrit: simple clinical technique for estimating fat concentration and energy value of human milk.BMJ, 1978